RecruitingNot ApplicableNCT06713187
Interleukin23 in Systemic Lupus
Role of Interleukin 23 in Systemic Lupus Erythematosus Related Interstial Lung Disease
Sponsor
Sohag University
Enrollment
90 participants
Start Date
May 1, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
assement of interleukin 23 in serum of patients with systemic lupus erythematosus related interstial lung disease .
Eligibility
Min Age: 18 YearsMax Age: 60 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a biological treatment called interleukin 23 for people with systemic lupus erythematosus related interstial lung disease. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 18 Years to 60 Years.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
BIOLOGICALinterleukin 23
assessment of interleukin 23 in Sera of patients using ELIZA
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06713187